12.44
price up icon6.23%   0.73
after-market Handel nachbörslich: 12.38 -0.06 -0.48%
loading
Schlusskurs vom Vortag:
$11.71
Offen:
$11.73
24-Stunden-Volumen:
779.72K
Relative Volume:
0.81
Marktkapitalisierung:
$975.05M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-4.3045
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
+7.06%
1M Leistung:
+2.47%
6M Leistung:
-36.24%
1J Leistung:
-34.28%
1-Tages-Spanne:
Value
$11.46
$12.90
1-Wochen-Bereich:
Value
$11.34
$12.90
52-Wochen-Spanne:
Value
$8.18
$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name
Firmenname
Nurix Therapeutics Inc
Name
Telefon
(415) 660-5320
Name
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Name
Mitarbeiter
286
Name
Twitter
Name
Nächster Verdiensttermin
2025-04-09
Name
Neueste SEC-Einreichungen
Name
NRIX's Discussions on Twitter

Vergleichen Sie NRIX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NRIX
Nurix Therapeutics Inc
12.44 975.05M 54.55M -193.57M -181.86M -2.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-17 Eingeleitet Leerink Partners Market Perform
2024-12-10 Eingeleitet BTIG Research Buy
2024-12-06 Eingeleitet BMO Capital Markets Outperform
2024-10-24 Eingeleitet UBS Buy
2024-10-11 Eingeleitet Jefferies Buy
2024-09-06 Fortgesetzt Robert W. Baird Outperform
2024-07-31 Eingeleitet Truist Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-03-09 Eingeleitet Barclays Overweight
2023-02-28 Eingeleitet Oppenheimer Outperform
2022-10-11 Eingeleitet Morgan Stanley Equal-Weight
2022-05-31 Hochstufung Wells Fargo Equal Weight → Overweight
2022-02-10 Eingeleitet Wells Fargo Equal Weight
2021-12-29 Eingeleitet H.C. Wainwright Buy
2021-10-14 Eingeleitet SVB Leerink Outperform
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-04-30 Fortgesetzt Piper Sandler Overweight
2021-04-30 Eingeleitet RBC Capital Mkts Outperform
2021-04-14 Eingeleitet Berenberg Buy
2020-11-19 Eingeleitet Robert W. Baird Outperform
2020-08-18 Eingeleitet JP Morgan Overweight
2020-08-18 Eingeleitet Needham Buy
2020-08-18 Eingeleitet Piper Sandler Overweight
2020-08-18 Eingeleitet Stifel Buy
Alle ansehen

Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten

pulisher
Jun 18, 2025

Analysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO) - The Globe and Mail

Jun 18, 2025
pulisher
Jun 17, 2025

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conf - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nurix Therapeutics (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

NuCana (NRIX) to Participate in Key Oppenheimer Conference | NRIX Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

(NRIX) Investment Analysis - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges By Investing.com - Investing.com South Africa

Jun 14, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Transcript : Nurix Therapeutics, Inc.Special Call - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | NRIX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - The Manila Times

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: Nurix Cancer Drug Achieves Complete Response in Hard-to-Treat Blood Cancers, New Trial Data Shows - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Nurix Therapeutics reports new KLHDC2 inhibitors - BioWorld MedTech

Jun 11, 2025
pulisher
Jun 10, 2025

Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail

Jun 10, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph

Jun 06, 2025
pulisher
Jun 06, 2025

Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat

Jun 06, 2025
pulisher
Jun 05, 2025

Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat

Jun 04, 2025
pulisher
Jun 03, 2025

(NRIX) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 02, 2025

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Nurix secures additional $15 million from Sanofi license deal - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat

Jun 01, 2025
pulisher
May 30, 2025

Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 30, 2025
pulisher
May 28, 2025

Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat

May 28, 2025

Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):